m-Rehab OSA : Impact of a Telerehabilitation Program Associated With CPAP on Severity Markers of Obstructive Sleep Apnea Syndrome (mRehabOSA)
Primary Purpose
Obstructive Sleep Apnea Syndrome
Status
Active
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Telerehabilitation solution (m-Rehab)
Sponsored by
About this trial
This is an interventional treatment trial for Obstructive Sleep Apnea Syndrome
Eligibility Criteria
Inclusion Criteria:
- Severe obstructive sleep apnea (apnea-hypopnea index ≥30 / hour)
- Body mass index ≥ 30 kg / m²
- age between 30 and 75 years old
- written consent
Exclusion Criteria:
- Presence of contraindications to perform exercise training (neuromuscular disease, orthopedic cause, acute coronary syndrome or stroke in the previous three months)
- Active infection, chronic inflammatory disease, cancer under treatment. Systemic treatment with immunosuppressants or corticosteroids
- Obstructive Sleep Apnea treated by Continuous Positive Airway Pressure or mandibular advancement device in the 3 months preceding inclusion
- Participation in a rehabilitation program scheduled within six months of inclusion
- Predominantly central sleep apnea syndrome (AC> 50%)
- Heart failure with Left Ventricular Ejection Fraction <40% known
- Bariatric surgery in the previous 6 months or bariatric surgery project in the 6 months
- Alcohol> 14 drinks per week
- Inability to understand and / or answer questionnaires.
- Refusal to use a smartphone or digital device
- Inability to access an internet connection at home.
- Subject in a period of relative exclusion with respect to another protocol or for which the maximum annual amount of compensation of € 4,500 has been reached.
- Subject not affiliated with a social security scheme, or not beneficiary of such a scheme.
- Pregnant or breastfeeding woman, patient unable to give her protected adult consent, vulnerable people
- Subject deprived of liberty by judicial or administrative decision
Sites / Locations
- CHU Montpellier
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Experimental arm
Control arm
Arm Description
Patients in the experimental group will be treated with CPAP (PRISMA, LOWENSTEIN®) and will have access to the m-Rehab® telerehabilitation program.
Patients in the experimental group will be treated with CPAP (PRISMA, LOWENSTEIN) and will receive the usual advice on adapted physical activity and nutrition during the initial consultation.
Outcomes
Primary Outcome Measures
Change from baseline daytime sleepness at 6 months
Epworth questionnaire
Change from baseline quality of life at 6 months
Functional Outcomes of Sleep Questionnaire (FOSQ)
Change from baseline systolic blood pressure at 6 months
Blood pressure : nocturnal systolic BP (ambulatory blood pressure measurement)
Change from baseline inflammation at 6 months
C-reactive protein in blood
Secondary Outcome Measures
Evolution of fatigue in experimental and control group
Pichot questionnaire
Evolution of quality of life in experimental and control group
EQ5D (EuroQol) questionnaire
Evolution of sleep quality in experimental and control group
Pittsburg questionnaire
Evolution of anxiety and depression in experimental and control group with Hospital Anxiety and Depression scale
Anxiety and depression will be evaluated with the HAD (Hospital Anxiety and Depression) scale (values 0-21 with higher score meaning a worse outcome).
Evolution of sleepiness in experimental and control group (Epworth)
Percentage of patients with Epworth fall> 2
Evolution of sleepiness in experimental and control group (IHSS)
Assessed by the Idiopathic Hypersomnia Severity Scale. The total score is 0 to 50 with a higher score indicating more drowsiness.
Evolution of sleepiness in experimental and control group (iterative sleep latency tests)
Evaluated by iterative sleep latency tests
Evolution of the architecture of sleep in experimental and control group
Architecture of sleep will be evaluated with polysomnography : Stages of sleep (Stages N1 N2, N3 and REM in minutes and %), sleep efficiency (%), micro-arousal index (number of events/hour)
Evolution of polysomnographic markers in experimental and control group
time spent under a SpO2 of 90%
Evolution of physical activity parameters in experimental and control group (IPAQ)
evaluated by International Physical Activity Questionnaire (IPAQ)
Evolution of physical activity parameters in experimental and control group (actimetry)
evaluated by actimetry (number of steps)
Evolution of nutritional parameters in experimental and control group
assessed by dietary calendar
Evolution of exercise tolerance in experimental and control group
assessed by exercise test on a cycloergometer
Evolution of anthropometric parameters in experimental and control group
ratio of waist circumference to hip circumference
Evolution of biological parameters in experimental and control group (fasting blood sugar)
Evolution of biological parameters in experimental and control group (total cholesterol)
Evolution of biological parameters in experimental and control group (LDL cholesterol)
Evolution of biological parameters in experimental and control group (HDL cholesterol)
Evolution of biological parameters in experimental and control group (triglycerides)
Evolution of biological parameters in experimental and control group (glycated haemoglobin (HbA1c))
Evolution of endothelial function in experimental and control group
assessed by endoPAT
Evolution of blood pressure profile parameters in experimental and control group
evaluated by ambulatory blood pressure measurement over 24 hours
Evolution of adherence to Continuous positive airway pressure (CPAP) in experimental and control group
Evolution of adherence to Continuous positive airway pressure (CPAP) in experimental and control group
Evolution of adherence to Continuous positive airway pressure (CPAP) in experimental and control group
Assessment of individual factors influencing CPAP adherence in experimental and control group
The individual factors studied are gender, body mass index and age.
Assessment of device-related factors influencing CPAP adherence in experimental and control group
The device-related factors are are the type of mask, fixed or autopilot mode and whether or not a humidifier is used. The factors of the CPAP are: residual IAH (number/hour), the pressure P90 (cmH2O), the leaks (% and liter/minute), the duration of deep sleep (minutes and %) evaluated by the CPAP.
Assessment of the incremental cost-utility ratio in experimental and control group
Full Information
NCT ID
NCT05049928
First Posted
August 20, 2021
Last Updated
September 13, 2023
Sponsor
University Hospital, Montpellier
1. Study Identification
Unique Protocol Identification Number
NCT05049928
Brief Title
m-Rehab OSA : Impact of a Telerehabilitation Program Associated With CPAP on Severity Markers of Obstructive Sleep Apnea Syndrome
Acronym
mRehabOSA
Official Title
m-Rehab OSA : Impact of a Telerehabilitation Program Associated With CPAP on Severity Markers of Obstructive Sleep Apnea Syndrome. Prospective, Randomized, Controlled, Multicenter Study
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
September 27, 2021 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
July 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Obstructive sleep apnea syndrome (OSA) is a common condition associated with major repercussions such as excessive daytime sleepiness and impaired quality of life as well as metabolic and cardiovascular complications. Continuous positive airway pressure (CPAP) remains the treatment of choice but its effectiveness remains limited, especially in reducing cardio-metabolic risk. Interventions to modify the lifestyle are therefore recommended in the management of OSA. The emergence of information and communication technologies is an opportunity for patients to have tools that promote self-management and behavioral changes. The recent development of telerehabilitation (TR) is a promising approach that has only been the subject of pilot studies. In a randomized, controlled and multicenter study, we propose to test the hypothesis according to which the use of a mobile TR solution, associated with continuous positive airway pressure (CPAP), will allow obese patients to adopt behavioral modifications to improve markers of severity of OSA. The analysis of big data (data-mining) will allow a better understanding of the motivational obstacles and levers.
Detailed Description
Statistical analysis plan The number of patients solicited for the study and the number of subjects included and randomized in each group will be reported on the flow chart. Premature stops (lost to follow-up, death, study withdrawals) and their reasons will be reported as well as any deviations from the protocol.
An initial descriptive analysis of each of the groups will be carried out. For qualitative variables, this description will include the number as well as the frequency of the different modalities. Concerning the quantitative variables, the description will include the number, the mean, the standard deviation, the median as well as the extreme values according to the distribution.
The comparability of the 2 groups will be verified for all the initial characteristics likely to influence the results. In the event of non-comparability on one or more parameters, an adjustment will be made on this or these parameters for the comparisons between groups of judgment criteria.
Analysis of the primary judgment criterion The variation in the evolution of the various main criteria will be compared between the 2 groups using a nonparametric means comparison test (Mann-Whitney test) or if the distribution turns out to be Gaussian and the conditions application are verified, a parametric test (Student's T).
Analysis of secondary endpoints The qualitative variables will be compared by a Chi-square test. Otherwise, if the conditions for performing this test are not met, Fisher's exact test will be used.
The quantitative variables will be compared between the two groups:
in the case of Gaussian variables, by a student's t test or an analysis of variance
in the case of non-Gaussian variables, by a Wilcoxon-Mann-Withney test
Longitudinal data (quality of life scores, physical activities) will be modeled by a mixed regression with the patient effect as a random variable. A linear regression model modeling the variation of the longitudinal endpoints will be fitted to the covariates having at least one trend (p <0.15) to the difference between the two arms of the study. A forward type procedure will be implemented to obtain a final multivariate model.
Management of missing data:
The IPTW method will be used. The lost to follow-up will be considered using a weighting on the inverse of the probability of being censored
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstructive Sleep Apnea Syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
180 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Experimental arm
Arm Type
Experimental
Arm Description
Patients in the experimental group will be treated with CPAP (PRISMA, LOWENSTEIN®) and will have access to the m-Rehab® telerehabilitation program.
Arm Title
Control arm
Arm Type
No Intervention
Arm Description
Patients in the experimental group will be treated with CPAP (PRISMA, LOWENSTEIN) and will receive the usual advice on adapted physical activity and nutrition during the initial consultation.
Intervention Type
Other
Intervention Name(s)
Telerehabilitation solution (m-Rehab)
Intervention Description
The telerehabilitation program consists of the following elements:
Mobile applications and website usable on smartphone and tablet for the patient.
Teleconsultation solution for the patient and the doctors.
Video conferencing solution for professionals involved in patient follow-up: educators in adapted physical activity, physiotherapists, psychologists, dieticians, etc.
Web interface for health professionals allowing the collection and monitoring of various parameters in physical activity and nutrition as well as progress in therapeutic education activities.
Withings® connected objects
Primary Outcome Measure Information:
Title
Change from baseline daytime sleepness at 6 months
Description
Epworth questionnaire
Time Frame
Between baseline and 6 month visit
Title
Change from baseline quality of life at 6 months
Description
Functional Outcomes of Sleep Questionnaire (FOSQ)
Time Frame
Between baseline and 6 month visit
Title
Change from baseline systolic blood pressure at 6 months
Description
Blood pressure : nocturnal systolic BP (ambulatory blood pressure measurement)
Time Frame
Between baseline and 6 month visit
Title
Change from baseline inflammation at 6 months
Description
C-reactive protein in blood
Time Frame
Between baseline and 6 month visit
Secondary Outcome Measure Information:
Title
Evolution of fatigue in experimental and control group
Description
Pichot questionnaire
Time Frame
Between inclusion and 6 month visit
Title
Evolution of quality of life in experimental and control group
Description
EQ5D (EuroQol) questionnaire
Time Frame
Between inclusion and 6 month visit
Title
Evolution of sleep quality in experimental and control group
Description
Pittsburg questionnaire
Time Frame
Between inclusion and 6 month visit
Title
Evolution of anxiety and depression in experimental and control group with Hospital Anxiety and Depression scale
Description
Anxiety and depression will be evaluated with the HAD (Hospital Anxiety and Depression) scale (values 0-21 with higher score meaning a worse outcome).
Time Frame
Between inclusion and 6 month visit
Title
Evolution of sleepiness in experimental and control group (Epworth)
Description
Percentage of patients with Epworth fall> 2
Time Frame
Between inclusion and 6 month visit
Title
Evolution of sleepiness in experimental and control group (IHSS)
Description
Assessed by the Idiopathic Hypersomnia Severity Scale. The total score is 0 to 50 with a higher score indicating more drowsiness.
Time Frame
Between inclusion and 6 month visit
Title
Evolution of sleepiness in experimental and control group (iterative sleep latency tests)
Description
Evaluated by iterative sleep latency tests
Time Frame
Between inclusion and 6 month visit
Title
Evolution of the architecture of sleep in experimental and control group
Description
Architecture of sleep will be evaluated with polysomnography : Stages of sleep (Stages N1 N2, N3 and REM in minutes and %), sleep efficiency (%), micro-arousal index (number of events/hour)
Time Frame
Between inclusion and 6 month visit
Title
Evolution of polysomnographic markers in experimental and control group
Description
time spent under a SpO2 of 90%
Time Frame
Between inclusion and 6 month visit
Title
Evolution of physical activity parameters in experimental and control group (IPAQ)
Description
evaluated by International Physical Activity Questionnaire (IPAQ)
Time Frame
Between inclusion and 6 month visit
Title
Evolution of physical activity parameters in experimental and control group (actimetry)
Description
evaluated by actimetry (number of steps)
Time Frame
Between inclusion and 6 month visit
Title
Evolution of nutritional parameters in experimental and control group
Description
assessed by dietary calendar
Time Frame
Between inclusion and 6 month visit
Title
Evolution of exercise tolerance in experimental and control group
Description
assessed by exercise test on a cycloergometer
Time Frame
Between inclusion and 6 month visit
Title
Evolution of anthropometric parameters in experimental and control group
Description
ratio of waist circumference to hip circumference
Time Frame
Between inclusion and 6 month visit
Title
Evolution of biological parameters in experimental and control group (fasting blood sugar)
Time Frame
Between inclusion and 6 month visit
Title
Evolution of biological parameters in experimental and control group (total cholesterol)
Time Frame
Between inclusion and 6 month visit
Title
Evolution of biological parameters in experimental and control group (LDL cholesterol)
Time Frame
Between inclusion and 6 month visit
Title
Evolution of biological parameters in experimental and control group (HDL cholesterol)
Time Frame
Between inclusion and 6 month visit
Title
Evolution of biological parameters in experimental and control group (triglycerides)
Time Frame
Between inclusion and 6 month visit
Title
Evolution of biological parameters in experimental and control group (glycated haemoglobin (HbA1c))
Time Frame
Between inclusion and 6 month visit
Title
Evolution of endothelial function in experimental and control group
Description
assessed by endoPAT
Time Frame
Between inclusion and 6 month visit
Title
Evolution of blood pressure profile parameters in experimental and control group
Description
evaluated by ambulatory blood pressure measurement over 24 hours
Time Frame
Between inclusion and 6 month visit
Title
Evolution of adherence to Continuous positive airway pressure (CPAP) in experimental and control group
Time Frame
Between inclusion and 6 month visit
Title
Evolution of adherence to Continuous positive airway pressure (CPAP) in experimental and control group
Time Frame
Between inclusion and 3 month visit
Title
Evolution of adherence to Continuous positive airway pressure (CPAP) in experimental and control group
Time Frame
Between inclusion and 1 month visit
Title
Assessment of individual factors influencing CPAP adherence in experimental and control group
Description
The individual factors studied are gender, body mass index and age.
Time Frame
Between inclusion and 6 month visit
Title
Assessment of device-related factors influencing CPAP adherence in experimental and control group
Description
The device-related factors are are the type of mask, fixed or autopilot mode and whether or not a humidifier is used. The factors of the CPAP are: residual IAH (number/hour), the pressure P90 (cmH2O), the leaks (% and liter/minute), the duration of deep sleep (minutes and %) evaluated by the CPAP.
Time Frame
Between inclusion and 6 month visit
Title
Assessment of the incremental cost-utility ratio in experimental and control group
Time Frame
At 6 month visit
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Severe obstructive sleep apnea (apnea-hypopnea index ≥30 / hour)
Body mass index ≥ 30 kg / m²
age between 30 and 75 years old
written consent
Exclusion Criteria:
Presence of contraindications to perform exercise training (neuromuscular disease, orthopedic cause, acute coronary syndrome or stroke in the previous three months)
Active infection, chronic inflammatory disease, cancer under treatment. Systemic treatment with immunosuppressants or corticosteroids
Obstructive Sleep Apnea treated by Continuous Positive Airway Pressure or mandibular advancement device in the 3 months preceding inclusion
Participation in a rehabilitation program scheduled within six months of inclusion
Predominantly central sleep apnea syndrome (AC> 50%)
Heart failure with Left Ventricular Ejection Fraction <40% known
Bariatric surgery in the previous 6 months or bariatric surgery project in the 6 months
Alcohol> 14 drinks per week
Inability to understand and / or answer questionnaires.
Refusal to use a smartphone or digital device
Inability to access an internet connection at home.
Subject in a period of relative exclusion with respect to another protocol or for which the maximum annual amount of compensation of € 4,500 has been reached.
Subject not affiliated with a social security scheme, or not beneficiary of such a scheme.
Pregnant or breastfeeding woman, patient unable to give her protected adult consent, vulnerable people
Subject deprived of liberty by judicial or administrative decision
Facility Information:
Facility Name
CHU Montpellier
City
Montpellier
ZIP/Postal Code
34080
Country
France
12. IPD Sharing Statement
Learn more about this trial
m-Rehab OSA : Impact of a Telerehabilitation Program Associated With CPAP on Severity Markers of Obstructive Sleep Apnea Syndrome
We'll reach out to this number within 24 hrs